Kevin Baudhuin has been president of Pregis’ North American protective packaging business since 2007.
He has now been promoted to president of global protective packaging where he will lead Pregis Protective Packaging Europe.
Baudhuin said the firm aimed to create a broad environmentally friendly product portfolio suitable for a number of markets, including medical and pharmaceutical products.
The company already offers its Superlite poly Mailer and EP-Flex Renew biodegradable film products.
‘We recognise that any sustainable solution must still meet other key requirements such as high performance and cost-effectiveness and we will therefore ensure that our products continue to satisfy all these criteria,’ said Baudhuin.
He added that the firm’s growth strategy would focus on three main areas of sustainability, innovation and customer partnerships.
Sustainability to drive Pregis product development in Europe
To focus on environmentally friendly products in 2011
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Britain's biotech potential (part II): world-class science, second-class support?
In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Finance
Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach
The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position
Finance
UK biotech venture capital rises 17% in Q1 2026 as deal activity surges 67% year-on-year, BIA figures show
Total UK biotech equity financing reached £552m in the first quarter of 2026, driven by a 17% quarterly rise in venture capital investment, according to BioIndustry Association data, though public markets remain dormant with no IPOs recorded since 2022